5-cholesten-3β-ol 3-(3-carboxypropanoate) | 1510-21-0

• 物质功能分类: 生物化工 - 提取物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5-cholesten-3β-ol 3-(3-carboxypropanoate)
• 英文别名: 4-[[(3S,10R,13R)-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4-oxobutanoic acid
• CAS: 1510-21-0
• 化学式: C₃₁H₅₀O₄
• 分子量: 486.736
• InChiKey: WLNARFZDISHUGS-RMFGFAPESA-N

物化性质

• 熔点：
  178 °C
• 沸点：
  586.0±43.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Predicted)
• 溶解度：
  氯仿（微溶）、甲醇（微溶、加热、超声处理）
• LogP：
  10.708 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  8.5
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品运输编号：
  NONH for all modes of transport
• WGK Germany：
  3
• 海关编码：
  29171900

制备方法与用途

胆固醇琥珀酸单酯是一种脂肪酸类物质，可用作药物制剂中高端剂型的研发材料，例如制备克拉霉素离子对脂质微球注射液或硫酸氢氯吡格雷与阿司匹林的复合双层片等。

反应信息

• 作为产物：
  描述：

  Cholesterin 在 4-二甲氨基吡啶 、 水 、 溶剂黄146 、 N,N'-二环己基碳二亚胺 、 锌 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 6.5h， 生成 5-cholesten-3β-ol 3-(3-carboxypropanoate)
  参考文献：
  名称：

  New preparation of steroidal 3-hemisuccinates

  摘要：

  3-羟基琥珀酸酯（3-(3-羧基丙酸酯)) XI-XV，源自胆固醇（I），(20R)-3β-羟基-21-去甲胆甾-5,22-二烯-24 20-酮（II），雌二醇（III），(20E)-21-甲氧羰基-3β-羟基孕烯-5,20-二烯（IV）和地高辛（V），通过醇类I-V和三氯乙醇（3-[4-(2,2,2-三氯乙氧基)-4-氧代丁酸酯] VI-X）的混合琥珀酸酯制备而成。在吡啶中用琥珀酸酐对II和IV进行常规酰化失败。

  DOI：

  10.1135/cccc19840306

文献信息

• Hydroxycholesterol immunoassay
  申请人：ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.

  公开号：US10197583B2

  公开（公告）日：2019-02-05

  Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.

  本研究提供了一种 22-羟基胆固醇、24S-羟基胆固醇、25-羟基胆固醇、26-羟基胆固醇或 27-羟基胆固醇的衍生物。还提供了与上述衍生物共轭的蛋白质。还提供了一种抗体组合物，其中包含与 22-羟基胆固醇、24S-羟基胆固醇、25-羟基胆固醇、26-羟基胆固醇或 27-羟基胆固醇特异性结合的抗体。此外，还提供了一种制造特异性结合 22-羟基胆固醇、24S-羟基胆固醇、25-羟基胆固醇、26-羟基胆固醇或 27-羟基胆固醇的抗体的方法。还提供了一种检测 22-羟基胆固醇、24S-羟基胆固醇、25-羟基胆固醇、26-羟基胆固醇或 27-羟基胆固醇的方法。此外，还提供了一种检测 22-羟基胆固醇、24S-羟基胆固醇、25-羟基胆固醇、26-羟基胆固醇或 27-羟基胆固醇的试剂盒。还提供了一种检测药物二期代谢中使用的一种或多种酶的方法。此外，还提供了一种检测合成 22-羟基胆固醇、24S-羟基胆固醇、25-羟基胆固醇、26-羟基胆固醇或 27-羟基胆固醇的酶的方法。还提供了一种评估患者多发性硬化症进展的方法。还提供了一种确定治疗患者多发性硬化症是否有效的方法。此外，还提供了一种评估患者亨廷顿氏病进展情况的方法。此外，还提供了一种确定治疗患者亨廷顿氏病是否有效的方法。
• Design of Hydrolytically Releasable Prodrugs for Sustained Release Nanoparticle Formulations
  申请人：Alferiev Ivan

  公开号：US20130296285A1

  公开（公告）日：2013-11-07

  A prodrug according to formula (I) wherein R 2 is a residue of a drug, said drug having a hydroxyl group by which the COOR 2 group is formed; Z is O or NH; m is 0 or 1; and R 3 is an organic moiety comprising a lipophilic group or a residue of a polymer, provided that Z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles. A method of treating a medical condition with a drug includes administering to a patient in need of the drug a prodrug as described above, the prodrug being capable of releasing the drug in the patient after the administration step.
• HYDROXYCHOLESTEROL IMMUNOASSAY
  申请人：ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.

  公开号：US20170219612A1

  公开（公告）日：2017-08-03

  Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.
• US9233163B2
  申请人：——

  公开号：US9233163B2

  公开（公告）日：2016-01-12
• New preparation of steroidal 3-hemisuccinates
  作者：Pavel Drašar、Ivan Černý、Vladimír Pouzar、Miroslav Havel

  DOI：10.1135/cccc19840306

  日期：——

  3-Hemisuccinates (3-(3-carboxypropanoates)) XI-XV, derived from cholesterol (I), (20R)-3β-hydroxy-21-norchola-5,22-dien-24 20-olide (II), estrone (III), (20E)-21-methoxycarbonyl-3β-hydroxypregna-5,20-diene (IV) and digitoxigenine (V), were prepared via the mixed succinates of the alcohols I-V and trichloroethanol (3-[4-(2,2,2-trichloroethoxy)-4-oxobutanoates] VI-X). The usual acylation of II and IV with succinic anhydride in pyridine failed.

  3-羟基琥珀酸酯（3-(3-羧基丙酸酯)) XI-XV，源自胆固醇（I），(20R)-3β-羟基-21-去甲胆甾-5,22-二烯-24 20-酮（II），雌二醇（III），(20E)-21-甲氧羰基-3β-羟基孕烯-5,20-二烯（IV）和地高辛（V），通过醇类I-V和三氯乙醇（3-[4-(2,2,2-三氯乙氧基)-4-氧代丁酸酯] VI-X）的混合琥珀酸酯制备而成。在吡啶中用琥珀酸酐对II和IV进行常规酰化失败。